Résumé - Mohammad Hossein Pourgholami

Academic Qualifications:

PhD Pharmacology, MSc Pharmaceutical Sciences

[Welsh School of Pharmacy, University of Wales, Cardiff, UK]

Appointments:

2004 - 2014: Principal Scientist, Department of Surgery, St. George Hospital, Kogarah, Sydney, Australia

1998 - 2004: Senior Scientist, Department of Surgery, St. George Hospital, Kogarah, Sydney, Australia

1992 - 1997: Associate Professor of pharmacology, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

1987 - 1992: Assistant professor of Pharmacology, Faculty of Medicine, Tehran & Shahid Beheshti University of Medical Sciences, Tehran, Iran

Key skills:

- In depth knowledge of pharmaceutical sciences (pharmacology, oncology drug development, pharmacokinetics, therapeutic drug monitoring and pharmacovigilance)
- Teaching of medical pharmacology including principals of drug action, drug development and organ-based drug application and utility
- Management of research and development projects including clinical trials
- Ability to conduct rigorous search of the medical literature using common databases to progress projects and also to use relevant information for preparing presentations and scientific reports (original papers, review articles and drug brochures)
- Ability to effectively present ideas and document complex medical concepts in both written and oral communications
- Working knowledge of the healthcare system including the ICH guidelines, GCP and other guidelines relevant to therapeutics
- Excellent verbal communication skills coupled with the ability to positively discuss the evidence about medicines with staff, clinical experts, clients and stakeholders
- Demonstrated ability to mentor team members and contribute positively to a spirit of team cooperation in a progressive scientific environment
- High level of self-motivation and demonstrated research potential evidenced by authorship of high quality, peer-reviewed research publications
- Excellent organisational, communication, record-keeping skills and ability to meet deadlines
- Ability to analyse metrics to assess progress against objectives

Professional Membership:

1-Australian Society of Medical research [ordinary member]
2-American Association for Cancer research [AACR; active member]
3-European Society for Cancer research [ordinary member]

4- Australia New Zealand Gynaecology Oncology (ANZGOG)

Community Engagement: A member of the St. George Hospital Scientific advisory Board.

Patents:
1- Australian provisional patent application titled "Nanoparticle compositions for the treatment of cancer" (Application No. 2014902024).
2- Compounds for the treatment of mTOR pathway related diseases (2013)
Patent Application No. 2012903365
3- Kinase inhibitors for the Treatment of Cancer, Provisional Application No. 2012901199
4- Method of treatment of cancer and compositions of use therein [PCT/AU02/00339]
5- VEGF Inhibition [PCT/AU05/001318]
6- Treatment of cancer (ABZ and Taxol) [PCT/AU05/001839]
7- HIF inhibition [PCT/AU08/001454]

Supervision and Mentoring:
Twenty four postgraduate (PhD, PharmD. and MSC) students (Direct supervisor or co-supervisor);

Research Funding:
Most of my research work has been funded by grants received from biotechnology/drug companies.

Other major research funding

- **Australian Research Council (ARC) grant:** (390,000.00 over 3 years 2014-2017) – **CIC**: "Targeted therapies using Sprouty proteins: Synthetic strategies to polyion complex micelles as smart nano-sized drug carriers for proteins"
- **Australian Research Council (ARC) grant:** ($450,000.00 over 3 years 2011-13) – **CIB**: "A platform for the efficient optimization of drug delivery using cross-linked micelles and thioclick-chemistry toward better anti-cancer treatment".

==========

Publications

Jiang, Y., Lu, H., Chen, F., Callari, M., Pourgholami M., Morris, D.L., Stenzel, M.H. : PEGylated Albumin-Based Polyion Complex Micelles for Protein Delivery. Biomacromolecules. 2016 Mar 14;17(3):808-17. doi: 10.1021/acs.biomac.5b01537. Epub 2016 Feb 9

Pillai, K., Pourgholami, M.H., Chua, T.C., Morris, D.L. : Prognostic significance of Ki67 expression in malignant peritoneal mesothelioma. American Journal of Clinical Oncology. (2015) Aug;38 (4):388-94. doi: 10.1097.

Ataie-Kachoie, P., Pourgholami, M.H., Bahrami, F., Badar, S., Morris, D. L.: Minocycline attenuates hypoxia-inducible factor-1α expression correlated with modulation of p53 and AKT/mTOR/p70S6K/4E-BP1 pathway in ovarian cancer: in vitro and in vivo studies. American Journal of Cancer Research (2015) 5, 575-588.

Noorani, L., Stenzel, M., Liang, M., Pourgholami, M.H., Morris, D.L. : Albumin nanoparticles increase the anticancer efficacy of albendazole in ovarian cancer xenograft model. Journal of Nanobiotechnology (2015) 13, 25 - 36.

Noorani, L., Pourgholami, M.H., Liang, M., Morris, D.L., Stenzel, M.: Albendazole loaded albumin nanoparticles for ovarian cancer therapy. European Journal of Nanomededicine (2014) 6, 227–236.

Bahrami, F., Pourgholami, M. H., Mekkawy, A. H., Rufener, L., Morris, D. L. : Monepantel induces autophagy in human ovarian cancer cells through disruption of the mTOR/p70S6K signalling pathway. American journal of cancer research (2014) 4, 558-571.

Bahrami, F., Morris, D. L., Rufener, L., Pourgholami, M. H. : Anticancer properties of novel aminoacetonitrile derivative monepantel (ADD 1566) in pre-clinical models of human ovarian cancer. American journal of cancer research (2014) 4, 545-557.

Bahrami, B. F., Ataie-Kachoie, P., Pourgholami, M. H., Morris, D. L. : p70 Ribosomal protein S6 kinase (Rps6kb1): an update. Journal of clinical pathology (2014) 67, 1019-25.

Ataie-Kachoie, P., Pourgholami, M. H., Richardson, D. R., Morris, D. L. : Gene of the month: Interleukin 6 (IL-6). Journal of clinical pathology (2014) 67, 932-937.

Mekkawy, A. H., Pourgholami, M. H., Morris, D. L. : Involvement of urokinase-type plasminogen activator system in cancer: an overview. Medicinal research reviews (2014) 34, 918-956.

Mekkawy, A. H., Pourgholami, M. H., Morris, D. L. : Human Sprouty1 suppresses growth, migration, and invasion in human breast cancer cells. Tumour biology (2014) 35, 5037-5048.

Ahmadirad, N., Shojaei, A., Javan, M., Pourgholami, M. H., Mirnajafi-Zadeh, J. : Effect of minocycline on pentylenetetrazol-induced chemical kindled seizures in mice. Neurological sciences (2013) 35, 571-576.

Pillai, K., Pourgholami, M. H., Chua, T. C., Morris, D. L. : Ki67-BCL2 index in prognosis of malignant peritoneal mesothelioma, American journal of cancer research (2013) 3, 411-423.

Ataie-Kachoie, P., Badar, S., Morris, D. L., Pourgholami, M. H. : Minocycline targets the NF-kappaB Nexus through suppression of TGF-beta1-TAK1-IkappaB signaling in ovarian cancer, Molecular cancer research (2013) 11, 1279-1291.

Pillai, K., Pourgholami, M. H., Chua, T. C., Morris, D. L. : Does the expression of BCL2 have prognostic significance in malignant peritoneal mesothelioma?, American journal of cancer research (2013) 3, 312-322.

Pillai, K., Pourgholami, M. H., Chua, T. C., Morris, D. L. : MUC1 has prognostic significance in malignant peritoneal mesothelioma, The International journal of biological markers (2013) 28, 303-312.

Pillai, K., Pourgholami, M. H., Chua, T. C., Morris, D. L. : MUC1 as a Potential Target in Anticancer Therapies, American journal of clinical oncology (2013) 28, 303 - 312.

Kast, R. E., Boockvar, J. A., Bruning, A., Cappello, F., Chang, W. W., Cvek, B., Dou, Q. P., Duenas-Gonzalez, A., Efferth, T., Focosi, D., Ghaffari, S. H., Karpel-Massler, G., Ketola, K., Khoshnevisan, A., Keizman, D., Magne, N., Marosi, C., McDonald, K., Munoz, M., Paranjpe, A., Pourgholami, M. H., Sardi, I., Sella, A., Srivenugopal, K. S., Tuccori, M., Wang, W., Wirtz, C. R., Halatsch, M. E. A : Conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care, Oncotarget (2013) 4, 502-530.

Ataie-Kachoie, P., Morris, D. L., Pourgholami, M. H. : Minocycline suppresses interleukine-6, its receptor system and signaling pathways and impairs migration, invasion and adhesion capacity of ovarian cancer cells: in vitro and in vivo studies, PloS one (2013) 8, e60817.

Pillai, K., Pourgholami, M. H., Chua, T. C., Morris, D. L. : Oestrogen receptors are prognostic factors in malignant peritoneal mesothelioma, Journal of cancer research and clinical oncology (2013) 139, 987-994.

Pourgholami, M. H., Ataie-Kachoie, P., Badar, S., Morris, D. L. : Minocycline inhibits malignant ascites of ovarian cancer through targeting multiple signaling pathways, Gynecologic oncology (2013) 129, 113-119.

Moghaddam, S. M., Amini, A., Wei, A. Q., Pourgholami, M. H., Morris, D. L. : Initial report on differential expression of sprouty proteins 1 and 2 in human epithelial ovarian cancer cell lines, Journal of oncology (2012) Article ID 373826.

Ataie-Kachoie, P., Pourgholami, M. H., Morris, D. L. : Inhibition of the IL-6 signaling pathway: a strategy to combat chronic inflammatory diseases and cancer, Cytokine & growth factor reviews (2013) 24, 163-173.

Mekkawy, A. H., Morris, D. L., Pourgholami, M. H. : (2012) HAX1 Augments Cell Proliferation, Migration, Adhesion, and Invasion Induced by Urokinase-Type Plasminogen Activator Receptor, Journal of oncology (2012) Article ID 950749.

Kim, Y., Pourgholami, M. H., Morris, D. L., Stenzel, M. H. : Effect of cross-linking on the performance of micelles as drug delivery carriers: a cell uptake study, Biomacromolecules (2012) 13, 814-825.

Pourgholami, M. H., Mekkawy, A. H., Badar, S., Morris, D. L. : Minocycline inhibits growth of epithelial ovarian cancer, Gynecologic oncology (2012) 125, 433-440.

Huang, C. Y., Pourgholami, M. H., Allen, B. J. : Optimizing radioimmunoconjugate delivery in the treatment of solid tumor, Cancer treatment reviews (2012) 38, 854-860.

Amini, A., Masoumi Moghaddam, S., Morris, D. L., Pourgholami, M. H. : The critical role of vascular endothelial growth factor in tumor angiogenesis, Current cancer drug targets (2012) 12, 23-43.

Mirarabshahii, P., Pillai, K., Chua, T. C., Pourgholami, M. H., Morris, D. L. : Diffuse malignant peritoneal mesothelioma--an update on treatment, Cancer treatment reviews (2012) 38, 605-612.

Masoumi Moghaddam, S., Amini, A., Morris, D. L., Pourgholami, M. H. : Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer, Cancer metastasis reviews (2012) 31, 143-162.

Bahrami, F., Morris, D. L., and Pourgholami, M. H. Tetracyclines: drugs with huge therapeutic potential, Mini reviews in medicinal chemistry (2012) 12, 44-52.

Amini, A., Masoumi Moghaddam, S., Morris, D. L., and Pourgholami, M. H. Utility of vascular endothelial growth factor inhibitors in the treatment of ovarian cancer: from concept to application, Journal of oncology (2012) Article ID 540791.

Wang, L., Chen, H., Pourgholami, M. H., Beretov, J., Hao, J., Chao, H., Perkins, A. C., Kearsley, J. H., and Li, Y. Anti-MUC1 monoclonal antibody (C595) and docetaxel markedly reduce tumor burden and ascites, and prolong survival in an in vivo ovarian cancer model, PloS one (2011) 6, e24405.

Pillai, K., Akhter, J., Pourgholami, M. H., and Morris, D. L. Peritoneal mesothelioma in a woman who has survived for seven years: a case report, Journal of medical case reports (2011) 5, 36.

Kim, Y., Pourgholami, M. H., Morris, D. L., and Stenzel, M. H. (2011) An optimized RGD-decorated micellar drug delivery system for albendazole for the treatment of ovarian cancer: from RAFT polymer synthesis to cellular uptake, Macromolecular bioscience (2011) 11, 219-233.

Wang, L., Chen, H., Liu, F., Madigan, M. C., Power, C. A., Hao, J., Patterson, K. I., Pourgholami, M. H., O'Brien, P. M., Perkins, A. C., and Li, Y. Monoclonal antibody targeting MUC1 and increasing sensitivity to docetaxel as a novel strategy in treating human epithelial ovarian cancer, Cancer letters (2011) 300, 122-133.

Mekkawy, A. H., De Bock, C. E., Lin, Z., Morris, D. L., Wang, Y., and Pourgholami, M. H. Novel protein interactors of urokinase-type plasminogen activator receptor, Biochemical and biophysical research communications (2010) 399, 738-743.

Pourgholami, M. H., Khachigian, L. M., Fahmy, R. G., Badar, S., Wang, L., Chu, S. W., and Morris, D. L. Albendazole inhibits endothelial cell migration, tube formation, vasopermeability, VEGF receptor-2 expression and suppresses retinal neovascularization in ROP model of angiogenesis, Biochemical and biophysical research communications (2010) 397, 729-734.

Zhao, Y., Pourgholami, M. H., Morris, D. L., Collins, J. G., and Day, A. I. Enhanced cytotoxicity of benzimidazole carbamate derivatives and solubilisation by encapsulation in cucurbit[n]uril, Organic & biomolecular chemistry (2010) 8, 3328-3337.

Pourgholami, M. H., Cai, Z. Y., Badar, S., Wangoo, K., Poruchynsky, M. S., and Morris, D. L. Potent inhibition of tumoral hypoxia-inducible factor 1alpha by albendazole, BMC cancer (2010) 10, 143-149.

Pourgholami, M. H., Cai, Z. Y., Chu, S. W., Galettis, P., and Morris, D. L. The influence of ovarian cancer induced peritoneal carcinomatosis on the pharmacokinetics of albendazole in nude mice, Anticancer research (2010) 30, 423-428.

Pourgholami, M. H., Szwajcer, M., Chin, M., Liauw, W., Seef, J., Galettis, P., Morris, D. L., and Links, M. Phase I clinical trial to determine maximum tolerated dose of oral albendazole in patients with advanced cancer, Cancer chemotherapy and pharmacology (2010) 65, 597-605.

Mekkawy, A. H., Morris, D. L., and Pourgholami, M. H. Urokinase plasminogen activator system as a potential target for cancer therapy, Future oncology (2009) 5, 1487-1499.

Chu, S. W., Badar, S., Morris, D. L., and Pourgholami, M. H. Potent inhibition of tubulin polymerisation and proliferation of paclitaxel-resistant 1A9PTX22 human ovarian cancer cells by albendazole, Anticancer research (2009) 29, 3791-3796.

Pourgholami, M. H., Cai, Z. Y., Wang, L., Badar, S., Links, M., and Morris, D. L. Inhibition of cell proliferation, vascular endothelial growth factor and tumor growth by albendazole, Cancer investigation (2009) 27, 171-177.

Ghous, Z., Akhter, J., Pourgholami, M. H., and Morris, D. L. Inhibition of hepatocellular cancer by EB1089: in vitro and in vive study, Anticancer research (2008) 28, 3757-3761.

Zhao, Y., Buck, D. P., Morris, D. L., Pourgholami, M. H., Day, A. I., and Collins, J. G. Solubilisation and cytotoxicity of albendazole encapsulated in cucurbit[n]uril, Organic & biomolecular chemistry (2008) 6, 4509-4515.

Pourgholami, M. H., Wangoo, K. T., and Morris, D. L. Albendazole-cyclodextrin complex: enhanced cytotoxicity in ovarian cancer cells, Anticancer research (2008) 28, 2775-2779.
Pourgholami, M. H., and Morris, D. L. Inhibitors of vascular endothelial growth factor in cancer, Cardiovascular & hematological agents in medicinal chemistry (2008) 6, 343-347.

Khalilzadeh, A., Wangoo, K. T., Morris, D. L., and Pourgholami, M. H. Epothilone-paclitaxel resistant leukemic cells CEM/dEpoB300 are sensitive to albendazole: Involvement of apoptotic pathways, Biochemical pharmacology (2007) 74, 407-414.

Cai, Z. Y., Galettis, P., Lu, Y., Morris, D. L., and Pourgholami, M. H. Pharmacokinetics of albendazole in New Zealand white rabbits: oral versus intraperitoneal administration, Anticancer research (2007) 27, 417-422.

Pourgholami, M. H., Yan Cai, Z., Lu, Y., Wang, L., and Morris, D. L. Albendazole: a potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor-bearing nude mice, Clinical cancer research : an official journal of the American Association for Cancer Research (2006) 12, 1928-1935.

Pourgholami, M. H., Akhter, J., Wang, L., Lu, Y., and Morris, D. L. Antitumor activity of albendazole against the human colorectal cancer cell line HT-29: in vitro and in a xenograft model of peritoneal carcinomatosis, Cancer chemotherapy and pharmacology (2005) 55, 425-432.

Pourgholami, M. H., and Morris, D. L. 1,25-Dihydroxyvitamin D3 in lipiodol for the treatment of hepatocellular carcinoma: cellular, animal and clinical studies, The Journal of steroid biochemistry and molecular biology (2004) 89-90, 513-518.

Pourgholami, M. H., Lu, Y., Wang, L., Stephens, R. W., and Morris, D. L. Regression of Novikoff rat hepatocellular carcinoma following locoregional administration of a novel formulation of clofazimine in lipiodol, Cancer letters (2004) 207, 37-47.

Caputo, A., Pourgholami, M. H., Akhter, J., and Morris, D. L. 1,25-Dihydroxyvitamin D(3) induced cell cycle arrest in the human primary liver cancer cell line HepG2, Hepatology research : the official journal of the Japan Society of Hepatology (2003) 26, 34-39.

Saberi, M., and Pourgholami, M. H. Estradiol alters afterdischarge threshold and acquisition of amygdala kindled seizures in male rats, Neuroscience letters (2003) 340, 41-44.

Mirnajafi-Zadeh, J., and Pourgholami, M. H. Hippocampal hyperexcitability facilitates amygdala kindling in rats, The Indian journal of medical research (2002) 116, 35-40.

Morris, D. L., Jourdan, J. L., Finlay, I., Gruenberger, T., The, M. P., and Pourgholami, M. H. Hepatic intra-arterial injection of 1,25-dihydroxyvitamin D3 in lipiodol: Pilot study in patients with hepatocellular carcinoma, International journal of oncology (2002) 21, 901-906.

Finlay, I. G., Stewart, G. J., Shirley, P., Woolfe, S., Pourgholami, M. H., and Morris, D. L. Hepatic arterial and intravenous administration of 1,25-dihydroxyvitamin D3--evidence of a clinically significant hepatic first-pass effect, Cancer chemotherapy and pharmacology (2001) 48, 209-214.

Morris, D. L., Jourdan, J. L., and Pourgholami, M. H. Pilot study of albendazole in patients with advanced malignancy. Effect on serum tumor markers/high incidence of neutropenia, Oncology (2001) 61, 42-46.

Akhter, J., Lu, Y., Finlay, I., Pourgholami, M. H., and Morris, D. L. 1alpha,25-Dihydroxyvitamin D3 and its analogues, EB1089 and CB1093, profoundly inhibit the in vitro proliferation of the human hepatoblastoma cell line HepG2, ANZ journal of surgery (2001) 71, 414-417.

Saberi, M., Jorjani, M., and Pourgholami, M. H. Effects of chronic estradiol benzoate treatment on amygdala kindled seizures in male rats, Epilepsy research (2001) 46, 45-51.

Pourgholami, M. H., Woon, L., Almajd, R., Akhter, J., Bowery, P., and Morris, D. L. In vitro and in vivo suppression of growth of hepatocellular carcinoma cells by albendazole, Cancer letters (2001) 165, 43-49.

Pourgholami, M. H., Akhter, J., and Morris, D. L. In vitro antiproliferative activity of a medium-chain triglyceride solution of 1,25-dihydroxyvitamin D3 in HepG2 cells, Anticancer research (2000) 20, 4257-4260.

Saberi, M., Pourgholami, M. H., and Jorjani, M. The acute effects of estradiol benzoate on amygdala-kindled seizures in male rats, Brain research (2001) 891, 1-6.

Finlay, I. G., Stewart, G. J., Pourgholami, M. H., Akhter, J., and Morris, D. L. The use of lipiodol and medium chain triglyceride as delivery agents for hepatic arterial administration of 1, 25-dihydroxyvitamin D3--a potential new treatment for hepatocellular carcinoma, Anticancer research (2000) 20, 2705-2709.

Pourgholami, M. H., Akhter, J., Finlay, I. G., and Morris, D. L. 1,25-dihydroxyvitamin D3 dissolved in lipiodol produces a sustained antiproliferative effect in the human hepatoblastoma cell line HepG2, Anticancer research (2000) 20, 723-727.

Pourgholami, M. H., Akhter, J., Lu, Y., and Morris, D. L. In vitro and in vivo inhibition of liver cancer cells by 1,25-dihydroxyvitamin D3, Cancer letters (2000) 151, 97-102.

Mirnajafi-Zadeh, J., Fathollahi, Y., and Pourgholami, M. H. Intraperitoneal and intraamygdala N(6)-cyclohexyladenosine suppress hippocampal kindled seizures in rats, Brain research (2000) 858, 48-54.

Mirnajafi-Zadeh, J., Pourgholami, M. H., Palizvan, M. R., Rostampour, M., and Fallahi, M. Anticonvulsant action of 2-chloroadenosine injected focally into the perirhinal cortex in amygdaloid kindled rats, Epilepsy research (1999) 37, 37-43.

Pourgholami, M. H., Majzoob, S., Javadi, M., Kamalinejad, M., Fanaee, G. H., and Sayyah, M. The fruit essential oil of Pimpinella anisum exerts anticonvulsant effects in mice, Journal of ethnopharmacology (1999) 66, 211-215.

Pourgholami, M. H., Kamalinejad, M., Javadi, M., Majzoob, S., and Sayyah, M. Evaluation of the anticonvulsant activity of the essential oil of Eugenia caryophyllata in male mice, Journal of ethnopharmacology (1999) 64, 167-171.

Mohammad, S., Abolhassan, A., and Pourgholami, M. H. Evaluation of the anticonvulsant profile of progesterone in male amygdala-kindled rats, Epilepsy research (1998) 30, 195-202.

Pourgholami, M. H., Rostampour, M., Mirnajafi-Zadeh, J., and Palizvan, M. R. Intra-amygdala infusion of 2-chloroadenosine suppresses amygdala-kindled seizures, Brain research (1997) 775, 37-42.

Pourgholami, M. H., Mirnajafi-Zadeh, J., and Behzadi, J. Effect of intraperitoneal and intrahippocampal (CA1) 2-chloroadenosine in amygdaloid kindled rats, Brain research (1997) 751, 259-264.

Pourgholami, M. H., and Goshadrou, F. Evidence for serotonergic system involvement in the effect of morphine on gastrointestinal motility in the rat, General pharmacology (1995) 26, 779-783.

Pourgholami, M. H., Brain, K. R., and Nicholls, P. J. High-performance liquid chromatographic determination of imide inhibitors of aromatase in biological samples, Journal of chromatography (1988) 424, 163-169.

Pourgholami, M. H., Nicholls, P. J., Smith, H. J., Daly, M. J., and Dyas, J. Inhibition of aromatase activity in the rat by aminoglutethimide and related compounds, Journal of steroid biochemistry (1987) 26, 309-312.